(-)-Cannabidiol
Tocris Bioscience, part of Bio-Techne | Catalog # 1570
Natural cannabinoid; GPR55 antagonist, weak CB1 antagonist, CB2 inverse agonist and AMT inhibitor
Key Product Details
Description
Natural cannabinoid; GPR55 antagonist, weak CB1 antagonist, CB2 inverse agonist and AMT inhibitor
Alternative Names
CBD
Product Description
(-)-Cannabidiol is a non-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo. GPR55 and weak CB1 antagonist (IC50 values are 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50 = 27.5 μM). Also inhibits FABPs and a weak agonist at TRP vanilloid receptors (EC50 = 3.5 μM). Reduces inflammation and LPS-induced cytokine production in cultured microglial cells.Product Specifications
Molecular Weight
314.47
Formula
C21H30O2
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
CAS Number
13956-29-1
PubChem ID
12302390
InChI Key
QHMBSVQNZZTUGM-ROUUACIJSA-N
SMILES
CCCCCC1=CC(O)=C([C@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 23.59 | 75 | |
| Ethanol | 23.59 | 75 |
Preparing Stock Solutions
for (-)-Cannabidiol
The following data is based on the product molecular weight 314.47
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.75 mM | 4.24 mL | 21.20 mL | 42.40 mL |
| 3.75 mM | 0.85 mL | 4.24 mL | 8.48 mL |
| 7.5 mM | 0.42 mL | 2.12 mL | 4.24 mL |
| 37.5 mM | 0.08 mL | 0.42 mL | 0.85 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Dos-Santos-Pereira Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-?B-dependent signaling and glucose consumption. Glia 2020 PMID: 31647138
- Deutsch A personal retrospective: Elevating Anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Front.Pharmacol. 2016 PMID: 27790143
- Thomas Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br.J.Pharmacol. 2007 PMID: 17245363
- Ryberg The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 2007 PMID: 17876302
- Petitet Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 1998 PMID: 9667767
- Costa Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br.J.Pharmacol. 2004 PMID: 15313881
Product Specific Notices for (-)-Cannabidiol
For research use only
Loading...
Loading...